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ABSTRACT: Background. Treatment of recurrent oropharyngeal cancer
is widely thought to have poor outcomes. Justification for treatment,
especially in advanced cases, can be difficult.
Methods. A systematic search of MEDLINE, Embase, and Cochrane data-
bases was conducted. Included studies reported specific recurrent oro-
pharyngeal cancer survival data.
Results. Twenty-two retrospective studies were included. Pooled 3-year
overall survival (OS) was 26% (95% confidence interval [CI] 5 22% to
29%; I squared 5 40.7%; p 5 .057). Pooled 5-year OS was 23% (95%
CI 5 20% to 27%; I squared 5 73.9%; p 5 .000). Surgical treatment
was superior to radiation (5-year OS 26% vs 16%, respectively; p <
.001). The 5-year OS improved over time: 18% in the pre-2000 cohort;
35% in the mixed pre-2000 and post-2000 group; and 51% in the post-
2000 cohort (p < .001).
Conclusion. Outcomes have improved considerably over the last 2 deca-
des, resulting in approximately 50% overall 5-year survival. Human papil-
lomavirus (HPV) status, patient selection, and improvements in care may
explain this.VC 2016 The Authors Head & Neck Published by Wiley Periodi-
cals, Inc. Head Neck 00: 000–000, 2016
KEY WORDS: oropharynx, malignancy, cancer, surgery, radiotherapy
INTRODUCTION
The treatment of oropharyngeal cancer recurrence is
widely thought to have poor outcomes, with a previous
systematic review reporting the 5-year overall survival
(OS) rate of 26%1 for all pharyngeal cancers including
nasopharyngeal, oropharyngeal, and hypopharyngeal.
Questions have therefore been raised about the justifica-
tion for such treatment, especially in advanced recurrence
cases,1 and consequently patients are usually offered pal-
liative treatment or best supportive care.2,3
The management of oropharyngeal cancer recurrence
has gained more prominence recently because of the rapid
rise in the incidence of oropharyngeal cancer4 over the
past decade. There has also been a change in causation,
with an increasing proportion caused by the human papil-
lomavirus (HPV). HPV-related oropharyngeal cancer
seems to be a distinct disease entity with a different
molecular mechanism and significantly improved progno-
sis compared to HPV-negative oropharyngeal cancer.5
Very recently, a study has suggested that HPV-positive
recurrence also demonstrates better 2-year survival rates
than HPV-negative tumors, and that this was especially
evident in patients who were treated surgically.6 Confir-
mation of these findings could result in a reappraisal of
the paradigms of the management of oropharyngeal can-
cer recurrence.
We therefore aimed to conduct a systematic review and
meta-analysis of the effectiveness of treatments of local/
locoregional recurrence of oropharyngeal squamous cell
carcinoma over time, and to explore the possible causes
of these trends through assessing HPV status and compli-
cation rates (as a surrogate for improved surgical
techniques).
METHODS
Search strategy
A systematic computer-based search was performed of
the following databases: MEDLINE, Embase, and the
Cochrane collaboration. No limit was placed on the year
of publication. The following search terms were used:
[Neoplasm OR Cancer OR Tumor OR Tumor OR Malig-
nancy] AND [Recurrent OR Residual OR Treatment fail-
ure OR Salvage] AND [Oropharynx OR Oropharyngeal
OR Tonsil OR Tongue base OR Base of tongue OR Soft
palate]. Reference lists of articles retrieved and previous
reviews were screened for further suitable studies. A full
review protocol is available on request.
*Corresponding author: H. Mehanna, Institute of Head and Neck Studies and
Education (InHANSE), School of Cancer Sciences, University of Birmingham,
Birmingham, B15 2TT, United Kingdom. E-mail: G.jones@bham.ac.uk
Additional Supporting Information may be found in the online version of this
article.
This is an open access article under the terms of the Creative Commons
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Inclusion and exclusion criteria
Two trained reviewers (S.C.J. and S.J.M.) independently
reviewed abstracts in accordance with a priori criteria, and
selected suitable studies for further evaluation of the full
manuscript. Abstracts were selected if they reported man-
agement of recurrent or residual oropharyngeal cancers.
Studies were included in the review if they fulfilled the
following a priori criteria: reported survival data specific
to recurrent oropharyngeal cancer, the minimal data that
had to be reported for inclusion was 2-year, 3-year, or 5-
year OS data taken from the date of management of
local/locoregional oropharyngeal recurrences; studies that
reported other subsites were included only if oropharynx-
specific survival data was either reported separately or
could be extracted via Kaplan–Meier curves or individual
patient data.
Studies dealing with isolated residual or recurrent nodal
disease were excluded. Studies were also excluded if not
published in English or in a language suitable for Optical
Character Recognition and translation software (Google
Translate; Google, Mountain View, CA). Both prospec-
tive and retrospective studies of cross-sectional, cohort,
and randomized designs were included.
Data extraction and study outcomes
A data extraction sheet (Excel; Microsoft, Redmond,
WA) was piloted using 10 studies. After amendment, this
was then used for collection of data from all included
studies. The 2 reviewers (S.C.J. and S.J.M.) independently
extracted data from selected articles. Data were collected
on the country of origin, study and patient characteristics,
dates of recruitment of patient cohort, initial and recurrent
treatment, complications, feeding, and survival outcomes.
HPV status was recorded where available. Where there
were discrepancies that were not resolved by discussion
between the 2 reviewers, adjudication was undertaken by
the senior author (H.M.).
Quality and risk of bias appraisal
Study quality and risk of bias were independently
assessed by the 2 reviewers. As all studies were non-
randomized, the Methodological Index for Non-
Randomized Studies7 tool was used. Noncomparative
studies were assessed for the following criteria: clearly
stated aim; inclusion of consecutive patients; prospective
data collection; appropriate endpoints; unbiased evalua-
tion of endpoints; appropriate length of follow-up; and
loss to follow-up not exceeding 5%. If studies were com-
parative, they were also assessed for: control group hav-
ing the gold standard intervention; having contemporary
groups; baseline equivalence of groups; prospective calcu-
lation of sample size; and statistical analysis adapted to
the study design.
Statistical analysis
All statistical analyses were performed in Stata 12.1.
An estimation approach was used to calculate the 95%
confidence intervals (CIs). By regarding the survival rates
as a binomial proportion, using p as the survival rate and
n (the number of patients), it was possible to calculate the
95% CIs using Jeffreys interval (recommended by Brown
et al8). To estimate the CI when n is small, and is
reported to be comparable to other methods when n is
large. A random-effect meta-analysis was performed and
a forest plot was generated for 3-year and 5-year OS
rates. Meta-regression was used to obtain a p value for
the difference in subgroups. Any p values < .05 are con-
sidered statistically significant.
Heterogeneity was assessed using the I2 index statistic,
which estimates the percentage of variability that is due
to heterogeneity rather than error in sampling (chance).
RESULTS
Search results and study selection
Using the search strategy described, we identified 1280
abstracts. We found 13 additional records by screening
reference lists of articles and previous reviews. We under-
took a full review of 138 articles. Of these, 116 articles
were excluded. The reasons for exclusion are stated in
Supplementary Figure S1, online only (Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses
flow diagram).
Characteristics of selected studies and treatment
modalities
Twenty-two articles were selected for inclusion and
analysis in the study (Table 1).6,9–29 The studies reported
on 1105 patients, a mean of 50 patients (range, 5–163)
per study, published between 1976 and 2014. Because
some of the studies included several cohorts for different
treatment modalities, data were collected on 27 cohorts.
Among these, 21 cohorts reported on the outcomes of sal-
vage surgery, 5 on salvage brachytherapy, 1 on reirradia-
tion 1/2 chemotherapy. Seventeen studies that reported
either 3-year OS or 5-year OS were included in the quan-
titative meta-analysis.
Quality and heterogeneity of included studies
The quality assessment of the included studies is
detailed in Supplementary Table S1, online only. All the
22 studies were retrospective studies. The median quality
assessment score of the studies according to the Methodo-
logical Index for Non-Randomized Studies checklist was
11 of a maximum of 16 (range, 8–12). Overall, a low
level of heterogeneity (I2 <40%; p > .05) was seen
across the studies, but significant heterogeneity was iden-
tified in the reporting of 5-year survival data (I2 5 73.9;
p 5 .00).
Overall survival rates
The pooled overall 3-year survival rate was 26% (95%
CI 5 22% to 29%) (I2 5 40.7%; p 5 .057; see Figure
1). The pooled overall 5-year survival rate was 23%
(95% CI 5 20% to 27%; I2 5 73.9%; p 5 .000; see
Figure 2).
Effect of treatment modality
We compared the outcomes of salvage surgery to non-
surgical treatment modalities of oropharyngeal cancer
recurrence (brachytherapy/reirradiation). Patients under-
going surgical salvage demonstrated a trend to better 3-
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year OS rate (27%) compared to brachytherapy/reirradia-
tion (21%; see Figure 1), but the difference was not stat-
istically significant (p 5 .057). Overall, heterogeneity
between the groups was low (I2 5 37.3%; p 5 .072).
Surgical treatment demonstrated a statistically signifi-
cant higher 5-year OS rate compared to brachytherapy
and reirradiation (26% vs 16%, respectively; p < .001;
see Figure 2). The 5-year surgical cohort exhibited signif-
icant heterogeneity (I2 5 76.1%; p 5 .000).
Survival trends over time
We also analyzed the results of treatment by the time-
period of patient recruitment to assess trends in survival
rates over time. We used the year 2000 as a cutoff.
Because there were some studies that reported on patients
recruited both before and after 2000 together, we included
these studies in a third group. Therefore, we had 3
groups: (1) pre-2000; (2) pre-2000 and post-2000; (3) and
post-2000.
Overall, there was a statistically significant improve-
ment in 5-year survival over time: 18% in the pre-2000
cohort; 35% in the mixed pre-2000 and post-2000 group;
and 51% in the post-2000 cohort (p < .001; see Figure
3). On comparing 5-year OS for the surgical cohort, the
survival rate had significantly increased from 20% (pre-
2000) to 35% (pre-2000 and post-2000) to 51% (post-
2000; p < .001). In the radiotherapy cohort, there were
only 2 groups (pre-2000 and pre-2000 and post-2000)
because no study post-2000 had recruited patients for
radiotherapy alone. Although 5 survival rates had
improved in this cohort from 14% to 32%, the difference
was not statistically significant (p 5 .093).
For the 3-year OS, there were only 2 studies examining
patients exclusively post-2000. We therefore combined
the last 2 groups (ie, pre-2000, and post-2000 and post-
2000) for meta-analysis. Overall, the 3-year OS rate had
improved from 23% to 35% (p value 5 .005; see Figure
4). The 3-year OS rate for the surgical cohort had
improved from 24% to 35% (p value 5 .007), whereas
for the radiotherapy cohort, it had improved from 19% to
32% (p value 5 .237).
Treatment-related mortality and complications
In the 19 studies that reported treatment-related mortal-
ity data specific for oropharyngeal cancer recurrences, 27
(2.9%) treatment-related deaths were reported in 936
patients. On comparing the pooled data by time period of
patient recruitment, treatment-related mortality had
reduced from 4.5% pre-2000 to 0.7% in the combined
(pre-2000 and post-2000) group, and no treatment-related
deaths in the studies recruiting patients post-2000.
Thirteen studies reported the incidence of major com-
plications, with a total of 72 reported complications
(14.8%) in 485 patients. On analyzing results by time
period of patient recruitment, the incidence of major
treatment-related complications showed a steady decline
from 22.8% pre-2000 to 15.2% in the combined (pre-
2000 and post-2000) group to 5.3% in the post-2000
group.
Effect of human papillomavirus
Only 2 studies reported the HPV status of patients.6,20
Neither of these could be included in the quantitative
meta-analysis because of lack of 3-year or 5-year OS
data. The study by Omura et al20 reported 3-year disease-
free survival (DFS) rates, but included only 4 patients
who were HPV-positive. As most of the patients who
underwent salvage surgery were HPV-negative, he con-
cluded that HPV status was of little relevance in his
study.
In a recent study, Fakhry et al6 reported on their analy-
sis of 49 patients with documented p16 status. The 29
patients with p16-positive disease who underwent salvage
surgery had significantly better 2-year OS rates after sal-
vage surgery (72% vs 45%; p 5 .004) compared with
p16-negative patients.
FIGURE 1. Pooled 3-year overall survival rates, overall and by
treatment modality. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
FIGURE 2. Pooled 5-year overall survival rates, overall and by
treatment modality. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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Functional outcomes
Eight studies reported functional outcomes, with 209 of
339 patients (61.6%) able to return to an oral diet after
treatment.
Prognostic factors
Although various studies assessed the significance of
prognostic factors determining success of surgical sal-
vage/reirradiation, only 3 studies separated oropharyngeal
cancers from other head and neck subsites.
Bachar et al10 found that increasing T classification and
N classification were significant predictors of time to
death.
Nichols et al19 reported that the ability to completely
resect the tumors and obtain negative margins was signifi-
cantly associated with improved survival (p < .01). His-
tory of alcohol abuse was also associated with poorer
survival. None of the other factors that they analyzed
(including age, sex, subsite, recurrent T and N classifica-
tions, smoking, and perineural invasion) were statistically
significant.
In the study by Zafereo et al,29 a disease- free interval
of >12 months (p < .01) and younger age (p 5 .03)
were associated with higher OS rates. Patients with recur-
rent T3 or T4 tumors and patients showed a trend toward
lower 3-year OS rates compared to T1 or T2, however,
the difference was not statistically significant (p 5 .07).
Similarly, patients with recurrent neck disease had a
lower 3-year survival rate than patients without recurrent
neck disease, but this difference was also not statistically
significant (p 5 .47).
DISCUSSION
Traditionally, the treatment of patients with oropharyn-
geal recurrence is considered to have a poor prognosis
and considerable morbidity, and, as a result, patients are
often offered palliative or supportive care. Our results
indicate that the outcomes of treatment of recurrent oro-
pharyngeal cancer seem to have improved considerably
over the last 2 decades, now resulting in OS of up to
50% over 5 years. Complications after treatment seem to
have reduced significantly over the past 2 decades, and
are now relatively low. In addition, deaths from treatment
of recurrence seem to be similar to those expected from
the treatment of primary cancers. These remarkable
improvements in the outcomes of treatment of recurrent
oropharyngeal cancer in recent years suggest the need for
reappraisal of the perception that outcomes of salvage
treatment are poor. Our findings point to the possible
need for a paradigm shift in the consideration of the treat-
ment options and counseling offered to patients with oro-
pharyngeal recurrence in the future, with appropriately
selected patients being offered the option of treatments
with a curative intent more frequently.
Overall, salvage surgery seems to have better survival
outcomes compared to nonsurgical treatment (reirradia-
tion). However, when adjusted for the period of recruit-
ment of patients, it would seem that the apparent
superiority of surgery may be due to the fact that the
included surgical studies were more recent than the radio-
therapy studies. Because more recent studies reported bet-
ter outcomes, surgery shows an apparent overall better
outcome than radiotherapy. On closer inspection, the effi-
cacy of surgery seems to be better than radiotherapy only
in cohorts recruited before the year 2000. In those studies
that include a mixture of patients recruited before and
after the year 2000, pooled overall 5-year survival seem
to be very similar between surgery and radiotherapy (35%
vs 32%, respectively). As for studies with patients
recruited after 2000, only surgical studies are included in
the meta-analysis, and so a comparison with radiotherapy
cannot be made. Therefore, we cannot conclude that sur-
gery is better than radiotherapy for the treatment of recur-
rent oropharyngeal cancer. Nevertheless, these surgical
studies show a remarkable improvement to 5-year OS of
51%. Similarly, a recent study examining oropharyngeal
cancer recurrence outcomes reported that surgical salvage
was strongly and independently associated with improved
survival after recurrence on multivariable analysis.6
FIGURE 3. Comparison of 5-year survival rates by modality and
time of recruitment. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
FIGURE 4. Comparison of 3-year survival rates by modality and
time of recruitment. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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Therefore, surgical salvage may be the best overall cura-
tive option for appropriately selected patients.
There may be several reasons for the marked improve-
ment in the outcomes of treatment of recurrent oropharyn-
geal cancer with time. Improvements in surgical
techniques with better reconstruction and better intraoper-
ative and postoperative care, as well as improvement in
radiotherapy techniques and quality assurance19 may have
been partly responsible for this improvement in outcomes.
The relatively low mortality rate and the remarkable
reduction in complication rates reported over time lend
support to this hypothesis. The realization of poor overall
outcomes of salvage surgery in the past, as well as publi-
cation of data suggesting prognostic factors for better out-
comes, may have led to improved selection of patients. It
could be postulated that this better selection, as well as
increased multidisciplinary working and centralization of
services in some countries, may have also led to better
outcomes. Importantly, the increase in the incidence of
HPV-related oropharyngeal cancer may also have a sig-
nificant role. Primary HPV-associated head and neck can-
cer has significantly better outcomes than HPV-negative
head and neck cancers. The recent study by Fakhry et al6
suggests that the improved prognosis may also apply to
patients with HPV-positive recurrence. In addition, the
study reported that patients who were p16-positive and
received surgery demonstrated significantly better survival
rates compared with p16-negative patients who had sur-
gery (72% vs 45% 2-year survival; p 5 .004). It is likely
that a combination of all the above factors has contributed
to this remarkable increase in OS.
The reporting of prognostic factors determining success
of salvage treatment was limited with only 3 studies, all
of which reported factors determining success of salvage
surgery. These studies reported different factors to be stat-
istically significant – including T classification,10 N clas-
sification,10 complete resection with negative margins,
alcohol abuse,19 disease-free interval29 and mean age at
presentation.29
Limitations of the study
There was a lack of uniformity in the presentation and
reporting of data by studies. We could not include a few
large studies of mixed head and neck sites because it was
not possible to extract or obtain oropharyngeal specific
survival data separate to other data.30–33 Some of the
studies included in the qualitative analysis could not be
included in the meta-analysis because of absence of either
3-year or 5-year OS data.6,15,20,21,27 Furthermore, reported
prognostic data were limited and disparate and could not
be subjected to meta-analysis.
Implications for research and practice
Research regarding the management of recurrent oro-
pharyngeal cancers is of relatively low quality and quan-
tity. Because outcomes seem to be improving
considerably, it is important that this area is studied more
and that the quality of studies is improved. It is recom-
mended that, in the future, authors should adhere to the
Strengthening the Reporting of Observational Studies in
Epidemiology guidelines34 for reporting studies and pres-
ent point estimates of data and its measure of variability.
Furthermore, because of the low number of patients being
treated for recurrent oropharyngeal cancer, national data-
bases should be set up to examine outcomes of these
patients and to explore better predictors of improved out-
come and patient selection. In addition, harmonization of
the definitions of the different predictive factors to be
studied would be of great benefit in the long term.
Furthermore, HPV status should be documented for all
patients, and its effect on the outcomes of patients with
oropharyngeal cancer recurrence should be explored fur-
ther. Finally, more research on functional and quality of
life outcomes and treatment cost in the management of
oropharyngeal recurrence are needed.
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